|Systematic (IUPAC) name|
|ATC code||R03 R03
|Mol. mass||211.258 g/mol|
|Solubility in water||9.7 mg/mL (20 °C)|
|Bioavailability||3% if inhaled, 40% if taken orally|
|Metabolism||Gastrointestinal and hepatic|
|Half life||6 hours|
|Pregnancy cat.||A(AU) C(US)|
|Legal status||℞-only (US)|
|Routes||Inhalation / tablets|
Orciprenaline (INN, also known as metaproterenol) is a bronchodilator used in the treatment of asthma. Orciprenaline is a moderately selective beta2-adrenergic receptor agonist that stimulates receptors of the smooth muscle in the lungs, uterus, and vasculature supplying skeletal muscle, with minimal or no effect on alpha-adrenergic receptors. The pharmacologic effects of beta adrenergic agonist drugs, such as orciprenaline, are at least in part attributable to stimulation through beta adrenergic receptors of intracellular adenyl cyclase, the enzyme which catalyzes the conversion of ATP to cAMP. Increased cAMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from many cells, especially from mast cells.
Brand names for orciprenaline include Alotec, Alupent, Metaprel and Novasmasol.